Related Experiment Video
Updated: Jun 11, 2025
04:25
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
9.0K
Genomic landscape and preclinical models of angiosarcoma
Annaleigh Benton1,2, Bozhi Liu1,2, Lauren E Gartenhaus1,2
1Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Molecular Oncology
|October 5, 2024
Summary
Angiosarcoma, a rare vascular cancer, has poor outcomes due to its aggressive nature and genetic complexity. Understanding its mutational landscape and available models is key to developing new therapies.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Angiosarcoma is a rare and aggressive cancer originating in blood or lymphatic vessels.
- Current treatments offer limited improvement, necessitating novel therapeutic strategies.
- High genetic heterogeneity complicates understanding and treatment of angiosarcoma.
Purpose of the Study:
- To review genomic alterations in angiosarcoma subtypes.
- To identify potential therapeutic targets.
- To highlight existing preclinical models for angiosarcoma research.
Main Methods:
- Comprehensive literature review of genomic alterations in angiosarcoma.
- Analysis of molecular and anatomic subtypes.
- Evaluation of preclinical models for therapeutic vulnerability assessment.
Main Results:
- Angiosarcomas display significant genetic heterogeneity but share common features within subgroups.
- Specific actionable targets have been identified through genomic profiling.
- Various preclinical models exist for studying angiosarcoma biology and testing therapies.
Conclusions:
- Integrating genomic data with disease models is crucial for identifying therapeutic vulnerabilities.
- Targeting identified pathways may offer new treatment avenues for angiosarcoma.
- Further research utilizing preclinical models is essential for advancing angiosarcoma treatment.
